Anandamide Signaling Can Involve TRPV1 as Well as Cannabinoid Receptors

An anandamide-related effect should not automatically be assigned to CB1. A review of alcohol–endocannabinoid research identifies TRPV1 as another relevant target requiring separate mechanistic testing.

The endogenous ligand has more than one possible target

Pava and Woodward discuss anandamide activation of TRPV1 alongside its relationship to the endocannabinoid system. They also summarize evidence that alcohol can potentiate TRPV1-mediated responses. An effect involving anandamide therefore does not identify its receptor solely from the ligand’s name.

Receptor specificity needs evidence

Experiments using selective interventions can help distinguish CB1, CB2 and non-cannabinoid-receptor contributions. A compound changing several pathways may be useful experimentally while leaving the specific mechanism unresolved.

A proposed pathway is not a clinical finding

The review presents non-CB1 signaling as a research direction in understanding alcohol-related behavior and physiology. It does not establish that TRPV1 explains all endocannabinoid effects or that manipulating it treats human alcohol dependence. This distinction also matters for cannabis claims: shared involvement of a biological target does not make an endogenous ligand, purified THC and a cannabis preparation equivalent interventions. The actual ligand, target and measured response must remain identifiable.

Related reading: Alcohol–Endocannabinoid Reviews Need to Keep Stages of Dependence Separate.

Research cited

Pava MJ, Woodward JJ. A Review of the Interactions between Alcohol and the Endocannabinoid System: Implications for Alcohol Dependence and Future Directions for Research (2012). The experiments discussed here are described through this supplied review.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Four-Day Session Washout Was Not Four Days of Cannabis Abstinence

The interval between experimental sessions should not be mistaken for verified cannabis abstinence. In a heavy-user study, participants could continue their usual cannabis routine despite a minimum four-day interval between treatments. The instructions defined the exposure history Ramaekers and colleagues allowed usual cannabis smoking during the study period. Participants were…

Spread the love

Read Article: A Four-Day Session Washout Was Not Four Days of Cannabis Abstinence

Booster Alcohol Doses Changed What a Cannabis Cross-Tolerance Study Tested

Maintaining alcohol concentrations with repeated booster doses tests a different exposure pattern from a single drink followed by falling concentrations. That difference mattered in a study of heavy cannabis users. The protocol aimed to sustain exposure Ramaekers and colleagues targeted steady alcohol concentrations across several hours, using booster doses as…

Spread the love

Read Article: Booster Alcohol Doses Changed What a Cannabis Cross-Tolerance Study Tested

The Primate THC Study Did Not Directly Measure Drug Metabolism as a Tolerance Mechanism

A behavioral pattern consistent with receptor adaptation does not independently rule out pharmacokinetic contributions. A primate study explicitly states that drug metabolism and disposition were not assessed. The behavioral comparison supported a receptor hypothesis McMahon found different degrees of tolerance and cross-tolerance among THC and synthetic cannabinoid agonists. The pattern…

Spread the love

Read Article: The Primate THC Study Did Not Directly Measure Drug Metabolism as a Tolerance Mechanism

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us